Loading clinical trials...
Loading clinical trials...
Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Conditions
Interventions
Erlotinib
RAD001
Locations
1
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
July 1, 2009
Primary Completion Date
November 1, 2014
Completion Date
November 1, 2014
Last Updated
May 1, 2025
NCT04585750
NCT07457346
NCT06636188
NCT07065630
NCT05526924
NCT07447050
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions